Dara Biosciences (DARA), which provides a liquid version of the Tamoxifen treatment for breast cancer, finds that the adherence of patients to the tablet form "is less than optimal."
In a survey, 14% of respondents said they miss two or more Tamoxifen doses a month, while 8% had swallowing difficulties.
Seven percent said a liquid version of Tamoxifen would boost their compliance and 22% said they'd be willing to try it.
Shares are +3.7% premarket. (PR)